|
Balance Sheet Cash Flow Statement 9605 Medical Center Dr., Ste. 300 Rockville, MD 20850 MD Tel. 240-599-4500 Fax 301-294-1900 |
Type: Public
On the web:
http://www.vandapharma.com
Employees:
24
Employee growth: (52.0%)
Vanda wants to gain an advantage in the field of neurological medicine. Vanda Pharmaceuticals is a pharmaceutical company that is developing several drugs for disorders of the central nervous system. The company's lead drug candidate, schizophrenia and bipolar disorder treatment Fanapt (formerly Fiapta, or iloperidone), received FDA approval in 2009. Other drug candidates are treatments for sleep disorders, including insomnia and sleep apnea, and depression. Vanda typically licenses development and commercialization rights for its compounds from companies including Bristol-Myers Squibb and Novartis.
Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($51.1)M
Officers:
Chairman: Argeris N. (Jerry) Karabelas
President, CEO, and Director: Mihael H. Polymeropoulos
Acting CFO and Treasurer: Stephanie R. Irish
Competitors:
Eli Lilly
Johnson & Johnson
Pfizer
